Q-omics provides the consensus-scored GPR27 profile across patient tissues and cancer cell-line models. GPR27 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, GPR27 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, GPR27 RNA expression shows 16,983 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KIRC, and THYM as cancer lineages where GPR27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR27 survival associations across molecular data types. GPR27 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR27 RNA expression–survival associations across cancer types. High GPR27 expression shows unfavorable associations in STAD, but favorable associations in BRCA, OV, UVM, LGG and ACC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for GPR27 RNA expression.
This table summarizes GPR27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR27 shows lower tumor expression in KIRC, COAD, KICH, HNSC and STAD and higher tumor expression in CHOL. The KIRC box plot shows higher GPR27 RNA expression in normal versus tumor tissue (log2 FC = −2.066, t-test p < 0.001).
This table shows molecular features associated with GPR27 in patient tissues and cancer cell lines. In patient samples, GPR27 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
